Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Hikma Pharmaceuticals Usa Inc. is currently navigating 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 4 distinct art units. This level of dispersion suggests that the company's patent prosecution is not concentrated under a lone individual or administrative group, but rather spread across multiple specialized units within the biotechnology sector.
The busiest examiner for this portfolio is D' AMBROSIO, THEA, who is managing 1 busiest examiner pending office action. Because there are 4 pending office actions in total, the workload is spread across 4 distinct examiners. For a practitioner, this means that the company's prosecution strategy must account for the varying styles and requirements of 4 distinct examiners across 4 distinct art units, rather than focusing on a single point of contact.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| D' AMBROSIO, THEA | 1 | 55.3% | +56.1% |
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| ROBERTS, LEZAH | 1 | 48.4% | +35.1% |
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18598526 | PHARMACEUTICAL COMPOSITIONS OF TOFACITINIB FOR ORAL ADMINISTRATION | SOROUSH, LAYLA | 182d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18598526 | PHARMACEUTICAL COMPOSITIONS OF TOFACITINIB FOR ORAL ADMINISTRATION | SOROUSH, LAYLA | 182d overdue |
| 18543158 | Buffered Lidocaine Injectable Formulations and Methods for Making Same | ROBERTS, LEZAH | 98d overdue |
| 18770925 | LIQUID DALBAVANCIN COMPOSITIONS | D' AMBROSIO, THEA | — |
| 18453360 | EPINEPHRINE SPRAY FORMULATIONS | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1622 | 1 |
| 1612 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18770925 | LIQUID DALBAVANCIN COMPOSITIONS | D' AMBROSIO, THEA | 1654 | §103§112DP | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18598526 | PHARMACEUTICAL COMPOSITIONS OF TOFACITINIB FOR ORAL ADMINISTRATION | SOROUSH, LAYLA | 1622 | §102§103Other | Non-Final OA | 182d overdue | Pending | Mar 07, 2024 |
| 18543158 | Buffered Lidocaine Injectable Formulations and Methods for Making Same | ROBERTS, LEZAH | 1612 | §103 | Final Rejection | 98d overdue | Pending | Dec 18, 2023 |
| 18453360 | EPINEPHRINE SPRAY FORMULATIONS | HUI, SAN MING R | 1627 | DP | Final Rejection | — | Pending | Aug 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial